Patents by Inventor Brian L. Hood
Brian L. Hood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11078260Abstract: Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma.Type: GrantFiled: January 12, 2018Date of Patent: August 3, 2021Assignee: University of Pittsburgh—Of The Commonwealth System of Higher EducationInventors: Soldano Ferrone, Xinhui Wang, Thomas P. Conrads, Elvira Favoino, Brian L. Hood
-
Publication number: 20180230205Abstract: Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma.Type: ApplicationFiled: January 12, 2018Publication date: August 16, 2018Applicant: University of Pittsburgh - Of The Commonwealth System of Higher EducationInventors: Soldano Ferrone, Xinhui Wang, Thomas P. Conrads, Elvira Favoino, Brian L. Hood
-
Patent number: 9902766Abstract: Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma.Type: GrantFiled: April 6, 2016Date of Patent: February 27, 2018Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Soldano Ferrone, Xinhui Wang, Thomas P. Conrads, Elvira Favoino, Brian L. Hood
-
Publication number: 20160207990Abstract: Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma.Type: ApplicationFiled: April 6, 2016Publication date: July 21, 2016Applicant: University of Pittsburgh - Of The Commonwealth Sys tem of Higher EducationInventors: Soldano Ferrone, Xinhui Wang, Thomas P. Conrads, Elvira Favoino, Brian L. Hood
-
Patent number: 9340608Abstract: Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma.Type: GrantFiled: June 27, 2013Date of Patent: May 17, 2016Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Soldano Ferrone, Xinhui Wang, Thomas P. Conrads, Elvira Favoino, Brian L. Hood
-
Publication number: 20150005183Abstract: This patent application discloses and describes proteins found to be differentially expressed between primary tumor breast cancer cells histologicaly defined as early stage (stage 0) breast cancer and primary breast cancer cells histologicaly defined as late stage (stage 3) breast cancer. These proteins can be used either individually or in specific combinations in diagnostic and prognostic protein assays on various biological samples from breast cancer patients to indicate the that a breast cancer patient's cancer is in an early, non-aggressive stage or in a late, aggressive stage. Determination of differential expression of these proteins can also be useful for indicating additional therapies to combat the aggressiveness of late stage breast cancer. The full length intact proteins can be assayed or peptides derived from these proteins can be assayed as reporters for these proteins.Type: ApplicationFiled: July 1, 2013Publication date: January 1, 2015Applicant: EXPRESSION PATHOLOGY, INC.Inventors: David Krizman, Marlene M. Darfler, Thomas P. Conrads, Brian L. Hood
-
Publication number: 20150005182Abstract: This patent application discloses and describes proteins found to be differentially expressed between primary tumor breast cancer cells that did not give rise to recurrent breast cancer disease after initial diagnosis and primary breast cancer cells that did give rise to recurrent breast cancer disease after initial diagnosis. These proteins can be used either individually or in specific combinations in diagnostic and prognostic protein assays on various biological samples from breast cancer patients to indicate the likelihood that a breast cancer patient's cancer will recur after initial diagnosis and treatment. Determination of differential expression of these proteins can also be useful for indicating additional therapies to combat the likelihood of recurrent breast cancer. The full length intact proteins can be assayed or peptides derived from these proteins can be assayed as reporters for these proteins.Type: ApplicationFiled: July 1, 2013Publication date: January 1, 2015Applicant: EXPRESSION PATHOLOGY, INC.Inventors: David Krizman, Marlene M. Darfler, Thomas P. Conrads, Brian L. Hood
-
Publication number: 20140010811Abstract: Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma.Type: ApplicationFiled: June 27, 2013Publication date: January 9, 2014Applicant: University of Pittsburgh - Of The Commonwealth System of Higher EducationInventors: Soldano Ferrone, Xinhui Wang, Thomas P. Conrads, Elvira Favoino, Brian L. Hood
-
Patent number: 8497354Abstract: Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma.Type: GrantFiled: June 15, 2011Date of Patent: July 30, 2013Assignee: University of Pittsburgh—Of The Commonwealth System of Higher EducationInventors: Soldano Ferrone, Xinhui Wang, Thomas P. Conrads, Elvira Favoino, Brian L. Hood
-
Publication number: 20120009194Abstract: Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma.Type: ApplicationFiled: June 15, 2011Publication date: January 12, 2012Inventors: Soldano Ferrone, Xinhui Wang, Thomas P. Conrads, Elvira Favoino, Brian L. Hood